Literature DB >> 15147729

An adenosine analog (IB-MECA) inhibits anchorage-dependent cell growth of various human breast cancer cell lines.

Mojtaba Panjehpour1, Fatemeh Karami-Tehrani.   

Abstract

A3 adenosine receptor agonists have been reported to influence cell death and survival. Here we report the effects of an A3 adenosine receptor agonist, IB-MECA, on the cell growth of human breast cancer cell lines, MCF-7 (estrogen receptor positive) and MDA-MB468 (estrogen receptor negative). Therefore, this study was aimed to investigate the expression and possible action of A3 receptor in the human breast cancer cell lines. IB-MECA, at 1-100 microM, resulted in a significant cell growth inhibition (P < 0.05) which reached the maximum at 48 h, in the cell lines. In both cell lines, agonist-induced effects were antagonized by pretreatment with a selective A3 adenosine receptor antagonist, MRS1220. Using RT-PCR method, further confirmation was provided by the presence of mRNA of A3 receptor in the cells. In addition, IB-MECA was able to inhibit forskolin-stimulated cAMP levels, which indicate the functional form of A3 receptor on the cell surface of these breast cancer cell lines. These results suggest that the inhibitory effect of IB-MECA on the growth of human breast cancer cell lines is mediated through activation of A3 adenosine receptor.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15147729     DOI: 10.1016/j.biocel.2003.12.001

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  13 in total

1.  Molecular mechanisms of A3 adenosine receptor-induced G1 cell cycle arrest and apoptosis in androgen-dependent and independent prostate cancer cell lines: involvement of intrinsic pathway.

Authors:  Mahmoud Aghaei; Mojtaba Panjehpour; Fatemeh Karami-Tehrani; Siamak Salami
Journal:  J Cancer Res Clin Oncol       Date:  2011-08-10       Impact factor: 4.553

2.  Antiproliferative effects of selective adenosine receptor agonists and antagonists on human lymphocytes: evidence for receptor-independent mechanisms.

Authors:  Anke C Schiedel; Svenja K Lacher; Carsten Linnemann; Percy A Knolle; Christa E Müller
Journal:  Purinergic Signal       Date:  2013-01-29       Impact factor: 3.765

3.  Targeting the inflammasome and adenosine type-3 receptors improves outcome of antibiotic therapy in murine anthrax.

Authors:  Serguei G Popov; Taissia G Popova; Fatah Kashanchi; Charles Bailey
Journal:  World J Biol Chem       Date:  2011-05-26

Review 4.  Purinergic signalling and cancer.

Authors:  Geoffrey Burnstock; Francesco Di Virgilio
Journal:  Purinergic Signal       Date:  2013-12       Impact factor: 3.765

5.  Human breast cancer cell line MDA-MB-231 expresses endogenous A2B adenosine receptors mediating a Ca2+ signal.

Authors:  Mojtaba Panjehpour; Marián Castro; Karl-Norbert Klotz
Journal:  Br J Pharmacol       Date:  2005-05       Impact factor: 8.739

6.  Mitochondrial and caspase pathways are involved in the induction of apoptosis by IB-MECA in ovarian cancer cell lines.

Authors:  Hamideh Abedi; Mahmoud Aghaei; Mojtaba Panjehpour; Sima Hajiahmadi
Journal:  Tumour Biol       Date:  2014-08-06

7.  Evaluation of RIP1K and RIP3K expressions in the malignant and benign breast tumors.

Authors:  Fatemeh Karami-Tehrani; Amin Rahimi Malek; Zahra Shahsavari; Morteza Atri
Journal:  Tumour Biol       Date:  2016-01-09

Review 8.  Adenosine receptors and cancer.

Authors:  P Fishman; S Bar-Yehuda; M Synowitz; J D Powell; K N Klotz; S Gessi; P A Borea
Journal:  Handb Exp Pharmacol       Date:  2009

9.  Synthesis of N6 ,N6-Dialkyl Adenine Nucleosides With In Situ Formed Hexaalkylphosphorus Triamides.

Authors:  Mahesh K Lakshman; Asad Choudhury; Suyeal Bae; Eliezer Rochttis; Padmanava Pradhan; Amit Kumar
Journal:  European J Org Chem       Date:  2009-01-01

Review 10.  Immunity, inflammation and cancer: a leading role for adenosine.

Authors:  Luca Antonioli; Corrado Blandizzi; Pál Pacher; György Haskó
Journal:  Nat Rev Cancer       Date:  2013-11-14       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.